GLP-1-Rezeptoragonisten (Inkretinmimetika) | Gelbe Liste
GLP-1-Rezeptoragonisten beim Typ-2-Diabetes: Einmal wöchentlich ist der täglichen Gabe ebenbürtig
Vildagliptin bei Typ-2-Diabetes
GLP-1R and Diabetes
Frontiers | GLP-1 Receptor Agonists and Coronary Arteries: From Mechanisms to Events
GLP-1 Agonist Effects on Glucagon Suppression
Kidney and Dialysis | Free Full-Text | GLP-1 Receptor Agonists in the Treatment of Patients with Type 2 Diabetes and Chronic Kidney Disease
Therapeutic potential of GLP-1 in type 2 diabetes mellitus | Download Table
GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes | Nature Reviews Nephrology
Neue Entwicklungen in der Therapie des Diabetes mellitus Typ 2 mit GLP-1-Agonisten - 04 - 2012 - Heftarchiv - AMT
Tirzepatid in den USA zugelassen | PZ – Pharmazeutische Zeitung
A Specific Gut Microbiota Dysbiosis of Type 2 Diabetic Mice Induces GLP-1 Resistance through an Enteric NO-Dependent and Gut-Brain Axis Mechanism - ScienceDirect
Novel Pharmacological Approaches to the Treatment of Type 2 Diabetes | Pharmacological Reviews
Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors | The Review of Diabetic Studies
Medikamentöse Therapie bei Diabetes Typ 2 - Diabetesinformationsportal
Semaglutid - Neuer GLP-1 Rezeptoragonist bei Typ-2-Diabetes • diabetologie-online
Glucagon-like peptide-1 - Wikipedia
Contemporary Updates on the Physiology of Glucagon like Peptide-1 and Its Agonist to Treat Type 2 Diabetes Mellitus | SpringerLink
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus | Nature Reviews Endocrinology
Oral GLP1 Gene Delivery by an Antibody-Guided Nanomaterial to Treat Type 2 Diabetes Mellitus | ACS Applied Materials & Interfaces
Clinical Focus on GLP-1 Agonists in Type 2 Diabetes Mellitus
